Document Detail


Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study.
MedLine Citation:
PMID:  2937533     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients with ovarian carcinoma refractory to chemotherapy received a sequential combination of ethinyl estradiol and medroxyprogesterone acetate in two dose regimens. There was no difference in therapeutic activity of the two dose regimens. Of 65 patients, nine (14%) responded to treatment and 13 (20%) had stable disease. Vascular complications occurred in three patients; hemiplegia developed in one of those. Nine patients had significant nausea and vomiting, and one experienced severe depression that required treatment withdrawal. The sequential and combined use of ethinyl estradiol and medroxyprogesterone acetate may provide an alternative treatment for certain patients with ovarian carcinoma that does not respond to optimum chemotherapy. Additional studies are required to determine if synergism exists between this treatment and other modalities of therapy. Further investigation is required into the vascular disorders that complicate therapy to determine whether appropriate preventive measures are possible.
Authors:
R S Freedman; P B Saul; C L Edwards; C J Jolles; D M Gershenson; L A Jones; E N Atkinson; W J Dana
Related Documents :
12893213 - The effects of co2 pneumoperitoneum on the survival of women with persistent metastatic...
21104163 - Extraparietal or lymphatic late relapse of neoplasms: confirmation by means of eus-fna ...
19546803 - Economic analysis of radiation therapy oncology group 97-14: multiple versus single fra...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer treatment reports     Volume:  70     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1986 Mar 
Date Detail:
Created Date:  1986-05-19     Completed Date:  1986-05-19     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  369-73     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Ethinyl Estradiol / administration & dosage
Female
Humans
Medroxyprogesterone / administration & dosage,  analogs & derivatives
Medroxyprogesterone Acetate
Middle Aged
Ovarian Neoplasms / drug therapy*
Receptors, Estrogen / analysis
Receptors, Progesterone / analysis
Vascular Diseases / chemically induced
Grant Support
ID/Acronym/Agency:
CA-31382/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Receptors, Estrogen; 0/Receptors, Progesterone; 520-85-4/Medroxyprogesterone; 57-63-6/Ethinyl Estradiol; 71-58-9/Medroxyprogesterone Acetate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hormonal therapies for breast cancer: can progestogens stimulate growth?
Next Document:  Angioplasty at coronary bifurcations: single-guide, two-wire technique.